Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AbbVie is conducting a Phase 2 clinical trial titled A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer. The study aims to assess the safety and efficacy of telisotuzumab adizutecan in combination with other drugs for treating metastatic colorectal cancer (mCRC), a prevalent cancer type worldwide.
Intervention/Treatment: The study tests telisotuzumab adizutecan, an investigational drug, alongside approved mCRC treatments like fluorouracil, leucovorin, oxaliplatin, bevacizumab, and panitumumab. The goal is to find effective treatment combinations for mCRC.
Study Design: This interventional study is randomized with a parallel assignment model and no masking. Its primary purpose is treatment, focusing on different dosing strategies of telisotuzumab adizutecan in combination with standard mCRC therapies.
Study Timeline: The study began on April 24, 2025, with primary completion expected in approximately six years. The latest update was submitted on July 30, 2025, indicating ongoing recruitment and progress.
Market Implications: This study could significantly impact AbbVie’s stock performance by potentially introducing a new effective treatment for mCRC, enhancing its oncology portfolio. Investor sentiment might be influenced by the study’s outcomes, especially if competitors are also advancing in similar therapeutic areas.
The study is ongoing, with further details available on the ClinicalTrials portal.